U.S. Appln. Serial No.: 10/569,812 Group Art Unit: 1621

Amendments to the Claims

OK TO ENTER

This listing of claims will replace all prior versions, and listings, of claims in the application:

/ML/ 08/07/2008

What is claimed is:

- (Cancelled).
- 2. (Cancelled).
- (Cancelled).
- (Currently Amended) A compound according to claim 4 11, wherein Z represents a bond or O.
- 5. (Currently Amended) A compound according to claim 4 11 of formula (Ia):

wherein:

 R^{13} is H, halo, CF₃, -OCF₃, cyano, nitro, OR¹⁴, SR¹⁵ or COR¹⁶; and R^{14}, R^{15}, R^{16} independently are H, C₁₋₆ alkyl or C₁₋₄ alkylaryl; or physiologically functional derivatives thereof.

- (Cancelled).
- (Cancelled).
- 8. (Cancelled).
- (Currently Amended) A pharmaceutical composition comprising a compound according to claim 4 11 and a pharmaceutically acceptable carrier.

U.S. Appln. Serial No.: 10/569,812 Group Art Unit: 1621

10. (Currently Amended) A process for preparation of compounds of formula (I) as defined in claim 4.11, wherein the process comprises:

(A) preparing a compound of formula (I), wherein Z is a bond and R¹ is an optionally substituted 5- or 6- membered aryl or heteroaryl, by reacting a compound of formula (II):

wherein R², Q and X are as previously defined for formula (I) and L¹ is a leaving group, with a reagent suitable to introduce the group R¹; or

(B) (i) preparing a compound of formula (I), wherein Z is O, S, SO, SO₂, NR⁴ or OCR⁴R⁵, by reacting a compound of formula (III):

$$X \rightarrow Q$$

wherein R², Q and X are as previously defined for formula (I) and Y is OH, SH, NHR⁴ or HOCR⁴R⁵, with a compound of formula (IV):

$$R^1L^2$$
 (IV)

wherein R^1 is defined above for compounds of formula (I) and L^2 represents a leaving group; and


- (ii) wherein Y is -SH, optionally followed by oxidizing the Y group to the corresponding SO or SO₂ group as required; or
- (C) preparing a compound of formula (I), wherein Z is -CR⁴R⁵O-, by reacting a compound of formula (III), wherein Y is -OH, with a compound of formula (V):

$$R^1CR^4R^5L^3$$
 (V)

wherein R¹ R⁴, R⁵ are defined above for compounds of formula (I) and L³ represents a leaving group; or

- (D) preparing a compound of formula (I), wherein Z is CH₂ and R¹ is an optionally substituted 5- or 6- membered aryl or heteroaryl, by reacting (i) a compound of formula (VI):
 - -3-

U.S. Appln. Serial No.: 10/569.812 Group Art Unit:



wherein Q, X and R2 are as defined above, with an optionally substituted 5- or 6membered aryl or heteroaryl nucleophile, which is a compound of formula (VII):

- (VII) wherein A is a 5- or 6- membered anyl or heteroaryl, R^{17} is H or one or more substituents and M is a metal and
 - (ii) reducing and eliminating a resultant or product alcohol formed form step (i); and,
- (E) optionally deprotecting compounds of formula (I) with a protecting group.

(New) A compound of formula (I):

$$R^1$$
_Z_Q_ \mathbb{P}^2 (I)

wherein:

R¹ is optionally substituted -C₄₋₁₂ alkyl, -C₂₋₁₀alkylcycloalkyl, -C₂₋₆alkylheterocycloalkyl, -C₂₋₆alkylaryl, optionally substituted 5- or 6-membered aryl or heteroaryl, provided that R¹ is not pyridinyl;

Z is a bond, CH₂, O, S, SO, SO₂, NR⁴, OCR⁴R⁵ or CR⁴R⁵O; or Z, R¹ and Q together form an optionally substituted fused tricyclic group:

Q is unsubstituted phenyl:

X is COOH:

R2 is CONH2:

R4 and R5 each independently is H, C1-6 alkyl or C1-4 alkylaryl; or physiologically functional derivatives thereof; and

further provided that when R1 is C4.13 alkyl, Z is other than a bond, O or CH2.